Precision Medicine for Idiopathic Hypersomnia

Sleep Med Clin. 2019 Sep;14(3):333-350. doi: 10.1016/j.jsmc.2019.05.007.

Abstract

Idiopathic hypersomnia (IH) is characterized by excessive daytime sleepiness despite normal or prolonged sleep. IH is distinguished from narcolepsy by the female predominance, severe morning inertia, continuous drowsiness (rather than sleep attacks), unrefreshing naps, absence of cataplexy, sleep onset in REM periods, and hypocretin deficiency. In IH, the multiple sleep latency test demonstrates low sensitivity, specificity, and reproducibility, compared with prolonged sleep monitoring. In some IH cases, an endogenous hypnotic peptide stimulating GABA receptors during wakefulness is suspected, which are improved by anti-GABA drugs. The benefits of modafinil, sodium oxybate, mazindol, and pitolisant were found in mostly retrospective studies.

Keywords: Drowsiness; GABA; Hypersomnia; Long sleep time; Modafinil; Sodium oxybate.

Publication types

  • Review

MeSH terms

  • Central Nervous System Stimulants / therapeutic use
  • Clarithromycin / therapeutic use
  • Flumazenil / therapeutic use
  • GABA Modulators / therapeutic use*
  • Humans
  • Idiopathic Hypersomnia / drug therapy*
  • Idiopathic Hypersomnia / metabolism
  • Idiopathic Hypersomnia / physiopathology
  • Mazindol / therapeutic use
  • Modafinil / therapeutic use
  • Orexins / metabolism
  • Piperidines / therapeutic use
  • Polysomnography
  • Precision Medicine
  • Sleep
  • Sodium Oxybate / therapeutic use
  • Wakefulness
  • Wakefulness-Promoting Agents / therapeutic use*

Substances

  • Central Nervous System Stimulants
  • GABA Modulators
  • HCRT protein, human
  • Orexins
  • Piperidines
  • Wakefulness-Promoting Agents
  • Flumazenil
  • pitolisant
  • Sodium Oxybate
  • Mazindol
  • Clarithromycin
  • Modafinil